secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001664710-26-000008
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics appoints Charles Newton to Board; Carl Gordon resigns effective March 9, 2026
--------------------------------------------------------------------------------

- Carl Gordon, Ph.D., resigned from the Board and Compensation Committee, effective March 9, 2026; no disagreement with the Company.
- Charles Newton appointed as Class III director, effective March 9, 2026, and will serve on Compensation and Audit Committees.
- Newton is former CFO of Lyell Immunopharma and has held senior roles at Bank of America, Credit Suisse, and Morgan Stanley.
- Newton currently serves on the boards of Novavax, Inc. and Coherus Oncology, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000008/0001664710-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000008/kros-20260220.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer